Form D · Biotechnology
Lonestar Medicines, Inc.
Boston, MA · CIK 0002111460
Offering snapshot reported Feb 23, 2026 · SEC filing
- Reported sold
- $25M Offering amount: $45M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 12, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 23, 2026 | Initial | $25,000,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-574347
Source: Form D, filed Feb 23, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Daley Bonificio | Executive, Promoter |
| Naveen Manu Daryani | Executive |
| Gianna Hoffman Luca | Director |
| Andrew Levin | Director |
| Stephen Basil Thomas | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Berkeley Street 18 Th Floor
Boston, MA, 02116
Boston, MA, 02116